⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

November 29, 2025Anticancer Research

Should Upfront Therapy With Androgen Receptor Signaling Inhibitors Be Used in All Japanese Patients With Metastatic Castration-sensitive Prostate Cancer?

Kenta Onishi Makito Miyake Shunsuke Hajikano Masaki Haramoto Fumisato Maesaka SHUYA HIRAO Kuniaki Inoue Toshihisa Saka Takashi Iwamoto Yukinari Hosokawa Kiyohide Fujimoto Nobumichi Tanaka

View Full Paper

Ask AI

Bookmark

Share

Abstract

Upfront ARSI therapy for Japanese patients with mCSPC significantly extended the time to CRPC but did not demonstrate a benefit in OS compared to vintage hormonal therapy.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Onishi et al. (2025) studied this question.

synapsesocial.com/papers/69402de12d562116f2903b3c https://doi.org/10.21873/anticanres.17894

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Comparison of oncological outcomes of upfront androgen receptor signaling inhibitors and combined androgen blockade in Japanese patients with metastatic castration-sensitive prostate cancer2024 · 3 citations
2Survival Benefit of ARSI Therapy in Japanese mCSPC : A Systematic Review and Meta‐AnalysisSystematic Review · 2026 · 1 citations
3Prognostic outcomes in Japanese patients with metastatic castration‐sensitive prostate cancer: Comparative assessments between conventional androgen deprivation therapy (ADT) and ADT with novel androgen receptor signal inhibitor2024 · 11 citations
4Prognostic factors for non‑metastatic castration‑resistant prostate cancer treated with androgen receptor signaling inhibitors2024 · 2 citations
5Novel Treatment Strategies for Low-Risk Metastatic Castration-Sensitive Prostate Cancer2024 · 7 citations